J Rheum Dis.  2014 Apr;21(2):87-90. 10.4078/jrd.2014.21.2.87.

A Case of Condyloma Acuminata in a Virgin Systemic Lupus Erythematosus Patient

Affiliations
  • 1Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea. wtchung@dau.ac.kr

Abstract

Anogenital infection with human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. The majority of HPV infections are transient and subclinical, with subsequent clearance by the immune system. However, in some individuals, especially those with impaired immunity, HPV infection may persist and result in condyloma acuminatum, pre-cancerous cervical abnormalities, as well as cervical cancer. Because of the intrinsic immunological aberrations and immunosuppressive treatment, patients with systemic lupus erythematosus (SLE) have higher prevalence of anogenital HPV infection, and SLE itself appears to be a major risk factor for HPV infection. HPV infection is sexually transmitted via genital contact; autogenesis of condyloma acuminatum without sexual contact is rare. In this case, a 27-year old virgin female with SLE was admitted to our clinic, presenting anogenital condyloma acuminata. It report that SLE patient can have a disease of anogenital HPV infection, despite the lack of sexual contact. Therefore, we recommend that patients with SLE have regular gynecological evaluations, in addition to prophylactic HPV vaccinations.

Keyword

Systemic lupus erythematosus; Condylomata acuminata; Human papillomavirus

MeSH Terms

Condylomata Acuminata
Female
Humans
Immune System
Lupus Erythematosus, Systemic*
Prevalence
Risk Factors
Uterine Cervical Neoplasms
Vaccination

Figure

  • Figure 1. Multiple, variable sized condyloma accuminata on external genitalia and perianal area.

  • Figure 2. Removed multiple, large, exophytic cauliflower-like masses on perianal area.


Reference

1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297:813–9.
Article
2. Lyrio LD, Grassi MF, Santana IU, Olavarria VG, Gomes Ado N, CostaPinto L, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013; 33:335–40.
Article
3. Forcier M, Musacchio N. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. Dermatol Ther. 2010; 23:458–76.
Article
4. Lee YH, Choe JY, Park SH, Park YW, Lee SS, Kang YM, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci. 2010; 25:1431–7.
Article
5. Klumb EM, Pinto AC, Jesus GR, Araujo M Jr, Jascone L, Gayer CR, et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010; 19:1485–91.
Article
6. Ornstein A, Hatchette T. Human papillomavirus and anogenital warts in children. CMAJ. 2012; 184:321.
Article
7. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157:218–26.
Article
8. Nicholls PK, Stanley MA. The immunology of animal papillomaviruses. Vet Immunol Immunopathol. 2000; 73:101–27.
Article
9. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity. 2005; 38:473–85.
Article
10. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356:1928–43.
Article
11. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367:1247–55.
Article
12. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an in-terim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369:2161–70.
Article
13. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013; 72:659–64.
Article
14. Santana IU, Gomes Ado N, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011; 30:665–72.
Article
15. Febronio MV, Pereira RM, Bonfa E, Takiuti AD, Pereyra EA, Silva CA. Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus. 2007; 16:430–5.
Article
Full Text Links
  • JRD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr